Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Finished Goods (2017 - 2025)

Historic Finished Goods for Neurocrine Biosciences (NBIX) over the last 7 years, with Q1 2025 value amounting to $13.6 million.

  • Neurocrine Biosciences' Finished Goods rose 8133.33% to $13.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $13.6 million, marking a year-over-year increase of 8133.33%. This contributed to the annual value of $12.8 million for FY2024, which is 406.5% up from last year.
  • As of Q1 2025, Neurocrine Biosciences' Finished Goods stood at $13.6 million, which was up 8133.33% from $12.8 million recorded in Q4 2024.
  • In the past 5 years, Neurocrine Biosciences' Finished Goods registered a high of $13.6 million during Q1 2025, and its lowest value of $7.5 million during Q1 2024.
  • In the last 3 years, Neurocrine Biosciences' Finished Goods had a median value of $11.9 million in 2023 and averaged $11.4 million.
  • Its Finished Goods has fluctuated over the past 5 years, first soared by 406.5% in 2024, then surged by 8133.33% in 2025.
  • Quarter analysis of 3 years shows Neurocrine Biosciences' Finished Goods stood at $12.3 million in 2023, then rose by 4.07% to $12.8 million in 2024, then rose by 6.25% to $13.6 million in 2025.
  • Its Finished Goods stands at $13.6 million for Q1 2025, versus $12.8 million for Q4 2024 and $11.5 million for Q3 2024.